Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2′-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome.

Leandro De Padua Silva, MD, Marcos de Lima, MD, Hagop Kantarjian, MD, Richard Champlin, MD, Stefan Faderl, MD, Sergio Giralt, MD, Partow Kebriaei, MD, Jan Davisson, RN, Eli Estey, MD, Guillermo Garcia-Manero, MD, Jean-Pierre Issa, MD, Farhad Ravandi, MD

Blood (2007) 110 (11): 1468.

https://doi.org/10.1182/blood.V110.11.1468.1468

Published: 2007

Journal Articles

Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen.

Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD, Susan O’Brien, MD, Zeev Estrov, MD, Farhad Ravandi, MD, Jorge Cortes, MD, Jianqin Shan, PhD, Jan Davisson, RN, Jean-Pierre Issa, MD

Blood (2007) 110 (11): 115.

https://doi.org/10.1182/blood.V110.11.115.115

Published: 2007

Journal Articles

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Elias Jabbour, MD, Hagop M. Kantarjian, M.D., Jorge Cortes, M.D., William G. Wierda, M.D., Ph.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Susan O’Brien, M.D., Farhad Ravandi-Kashani, M.D., Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Jan Davisson, BS, ADN, Francis Giles, M.D., Jianqin Shan, Ph.D., Jean-Pierre Issa, M.D.

Blood (2006) 108 (11): 2652.

https://doi.org/10.1182/blood.V108.11.2652.2652

Published: 2006

Journal Articles

Decitabine Induces High Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML).

Elias Jabbour, Susan O’Brien, Farhad Ravandi-Kashani, Jorge Cortes, Gautam Borthakur, Srdan Verstovsek, Guillermo Garcia-Manero, Francis Giles, Lourdes Zanoria, Jan Davisson, Jean-Pierre Issa, Hagop M. Kantarjian

Blood (2006) 108 (11): 2655.

https://doi.org/10.1182/blood.V108.11.2655.2655

Published: 2006

Journal Articles

A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)

Varsha Gandhi, John M. Kilpatrick, William Plunkett, Mary Ayres, Leigh Harman, Min Du, Shanta Bantia, Jan Davisson, William G. Wierda, Stefan Faderl, Hagop Kantarjian, Deborah Thomas

Blood (2005) 106 (13): 4253–4260.

https://doi.org/10.1182/blood-2005-03-1309

Published: 2005

NARROW

Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2′-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome.

Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen.

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Decitabine Induces High Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML).

A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)

Email alerts

ASH Publications

American Society of Hematology

Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2′-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome.

Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen.

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Decitabine Induces High Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML).

A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only